Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
42 Results for "
Tropomyosin receptor kinase
" in MedChemExpress (MCE) Product Catalog:
Products (42)
42 Results for "Tropomyosin receptor kinase" in MCE Product Catalog:
17
17 Publications Verification
Synonyms: LOXO-101; ARRY-470
Target:
Research Areas:
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
17
17 Publications Verification
Synonyms: LOXO-101 sulfate; ARRY-470 sulfate
Target:
Research Areas:
Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
7
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
4
4 Cited Publications
Target:
Research Areas:
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .
1
1 Cited Publications
Synonyms: Diphosphofructose; Esafosfan; FDP
Category:
Cardiovascular Disease Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields
Target:
1
1 Cited Publications
Target:
Research Areas:
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .
1
1 Cited Publications
Cat. No.: HY-P7308
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NTRK1; Tyrosine kinase receptor A; Neurotrophic receptor Tyrosine kinase 1; P140-TrkA; TRKA; Gp140trk; TRK; Trk-A; MTC; Neurotrophic Tyrosine kinase receptor Type 1; High Affinity Nerve Growth Factor receptor; Tyrosine-Protein kinase receptor; Neurotrophic Tyrosine kinase, receptor, Type 1; Tyrosine kinase receptor; TRK1-Transforming Tyrosine kinase Protein; Oncogene TRK; Tropomyosin receptor kinase A; TRK1; Tropomyosin-Related kinase A
Species:
Human
Source:
HEK293
Cat. No.: HY-P99297
CAS No.: 2171034-69-6
Synonyms: ZTS-00508841
Target:
Research Areas:
Cat. No.: HY-137465
CAS No.: 2412055-93-5
Target:
Research Areas:
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC50 = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC50 = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .
Cat. No.: HY-46531
CAS No.: 2412056-27-8
Target:
Research Areas:
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .
Synonyms: REC 0559
Target:
Research Areas:
Udonitrectag (REC 0559) is a nerve growth factor peptide mimetic and a TrkA receptor binder. Udonitrectag binds to the TrkA receptor, thereby mimicking anti-Apoptotic activity and corneal trophic activity. Udonitrectag promotes the healing of corneal epithelium and stroma. Udonitrectag is applicable to research related to neurotrophic keratitis .
Cat. No.: HY-175483S
CAS No.: 3087336-56-6
Cat. No.: HY-171450
CAS No.: 1802770-18-8
Target:
Research Areas:
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .
Cat. No.: HY-177082
CAS No.: 2396516-98-4
Target:
Research Areas:
Eratrectinib (Example 1) is a Trk inhibitor. Eratrectinib can be studied in research for tropomyosin receptor kinase-related diseases and cancers .
Cat. No.: HY-141864
CAS No.: 2655557-54-1
Target:
Research Areas:
ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
Cat. No.: HY-169546
CAS No.: 296888-45-4
Target:
Research Areas:
TrkA-IN-7 (Compound 4) is an inhibitor of Tropomyosin Receptor Kinase A (TrkA) with a Kd value of 40 μM .
Cat. No.: HY-144424
CAS No.: 2700265-62-7
Target:
Research Areas:
Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC50 = 1.4, 1.8 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .
Cat. No.: HY-157168
Target:
Research Areas:
TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM .
Cat. No.: HY-144423
CAS No.: 2700265-61-6
Target:
Research Areas:
Trk-IN-10 (Compound 14j) is a potent inhibitor of TRK (IC50 = 0.86, 6.92 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .
Cat. No.: HY-12866R
CAS No.: 1223403-58-4
Synonyms: LOXO-101 (Standard); ARRY-470 (Standard)
Target:
Research Areas:
Larotrectinib (Standard) is the analytical standard of Larotrectinib. This product is intended for research and analytical applications. Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
